Kevin Rakin has been our chief executive officer and a member of our board of directors since February 2021. Since October 2013, Mr. Rakin has been a co-founder and partner of HighCape, and he brings more than 30 years of experience as an executive and investor in the life sciences industry. Mr. Rakin also serves as chief executive officer and chairman of the board of HighCape I. He served as the president of SRM from June 2011 to November 2012. Prior to joining SRM, Mr. Rakin was the chairman and chief executive officer of ABH from 2007 until its acquisition by SRM in 2011. Before that, he served as an executive-in-residence at Canaan Partners, a venture capital firm. Until its merger with Clinical Data in 2005, Mr. Rakin was the co-founder, president and chief executive officer of Genaissance, a pharmacogenomics company. He is currently on the boards of Athena Therapeutics, Inc. (chairman), Aziyo Biologics, Inc. (chairman), Cybrexa, Inc., Oramed Pharmaceuticals, Inc., Wellinks, Inc., a subsidiary of Convexity Scientific, Inc. (chairman) and Nyxoah. Mr. Rakin received an MBA from Columbia University and a B.Com. (Hons) from the University of Cape Town, South Africa. Mr. Rakin’s qualifications to serve on the board include his extensive experience in the life sciences industry, as both an executive and an investor and his network of contacts in the industry.
Matt Zuga has been our chief financial officer and chief operating officer since February 2021. Since October 2013, Mr. Zuga has been a co-founder and partner of HighCape, and he brings more than 25 years of life sciences investment and banking experience. He currently serves as chief financial officer, chief operating officer and director of HighCape I. From August 2012 to September 2013, Mr. Zuga was a managing director of Syngenta Ventures Pte Ltd, an investment vehicle of Syngenta Corp. He was also the founder and managing member of Red Abbey, an investment company, from January 2004 to August 2012. Prior to Red Abbey, Mr. Zuga was a managing director and the head of life sciences investment banking at Legg Mason from 1999 to 2003. He is currently on the boards of Aziyo Biologics, Inc., AgriMetis, LLC, Alba Therapeutics Corporation and MF Fire, Inc. Mr. Zuga received an MBA from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill and a B.S. in Business Administration/Finance from Ohio State University. Mr. Zuga’s qualifications to serve on the board include his extensive experience in the life sciences industry, his network of contacts in the industry and his background in investing and investment banking.
David Colpman will serve on our board of directors following the completion of this offering. From July 2014 to March 2020, Mr. Colpman was the managing partner of Colpman Consulting Ltd, a business development consultancy. Prior to this, Mr. Colpman was a senior vice president at Shire Plc from 1999 to 2014. Prior to Shire Plc, Mr. Colpman had senior roles in business development at Novo Nordisk A/S, Glaxo Wellcome Plc and Boots Pharmaceuticals Ltd. Mr. Colpman serves as a member on the board of directors of HRA Pharma, SA, Forendo Pharma Ltd, Orexo AB and HighCape I. He is also an advisor to Sunstone Capital and HighCape Capital. Mr. Colpman received a B.Sc. from Portsmouth University in the field of pharmacy. Mr. Colpman’s qualifications to serve on the board include his substantial expertise in business development and his network of contacts in the industry.
Antony Loebel, M.D., will serve on our board of directors following the completion of this offering. Dr. Loebel has been the President and CEO of Sunovion, a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions from April 1st, 2019. He also serves as a Director of Sunovion and as an Executive Officer of Sumitomo Dainippon Pharma Co., Ltd (the parent company of Sunovion). His prior industry experience includes seven years in drug development and medical affairs roles at Pfizer from 2001 to 2007. Since 2007, Dr. Loebel has been employed at Sunovion (or a predecessor company); he was Executive Vice President and Chief Medical Officer for 8 years until assuming the CEO role in 2019. Dr. Loebel also serves on the board of directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and HighCape I. Dr. Loebel is a board-certified psychiatrist, a clinical assistant professor of psychiatry at the New York University School of Medicine, a Fellow of the American Psychiatric Association (APA) and a Fellow of the American College of Neuropsychopharmacology (ACNP). For his achievements in advancing new treatments for central nervous system disorders, Dr. Loebel received the 2015 Award for Leadership from the International Society for CNS Drug Development (ISCDD) and the 2019 CNS Summit Leadership Award. He was also selected by PharmaVOICE in 2019 and 2013 as one of the “100 Most Inspiring People” in the pharmaceutical industry. Dr. Loebel earned an M.D. from the University of Washington School of Medicine in Seattle. He completed his residency in Psychiatry and a research fellowship in Clinical Neurosciences at Zucker Hillside Hospital in Glen Oaks, New York. Dr. Loebel received a B.A. from the University of Washington. Mr. Loebel’s qualifications to serve on the board include his extensive experience in the life sciences industry, his reputation in the field and his scientific expertise.
Robert Taub will serve on our board of directors following the completion of this offering. Since July 2009, Mr. Taub has been the co-founder and chairman of Nyxoah, a publicly traded company (Euronext: NYXH) which is developing implants to treat Obstructive Sleep Apnea. Mr. Taub was also the chairman of Neuroderm, a publicly traded biotech company, from November 2013 until it was sold to Mitsubishi-Tanabe for $1.1 billion in 2017. In 1995, Mr. Taub founded and served as president, chief executive officer and a member of the board of directors of Omrix, a biopharmaceutical company that marketed biological products for the biosurgical and immunotherapy markets that was sold to Johnson & Johnson in 2008. Prior to establishing Omrix, Mr. Taub co-founded Octapharma AG, a human plasma fractionator, where he served from 1983 to 1995. Prior to Octapharma AG, he held various general management and sales and marketing positions with Monsanto Company, Baxter Travenol Laboratories and the Revlon Health Care Group. Mr. Taub has been director of Maya Gold and Silver since November 2016 and a director of HighCape I since February 2020. He received a B.A. from RUCA Antwerp University and an MBA from INSEAD in Fontainebleau, France. Mr. Taub’s qualifications to serve on the board include his extensive experience in the life sciences industry, his leadership experience and his business development expertise.